Navigation Links
Precise Timing Enabled Pig-to-rat Transplants To Cure Diabetes

Scientists at Washington University School of Medicine in St. Louis have learned that a temporal "window of opportunity" was critical to their earlier successes in treating diabetic rats with embryonic pig tissues.

In those experiments, published in 2004, researchers were surprised to find that they didn't have to give anti-rejection drugs to diabetic rats treated with embryonic pig cell transplants. They had expected rats that received no immune suppression would reject the transplants. Instead, the new tissues engrafted with little difficulty, curing the rats of their diabetes.

In a new study to be published in the September issue of Transplant Immunology and currently available online, senior investigator Marc R. Hammerman, M.D., the Chromalloy Professor of Renal Diseases in Medicine, presents evidence that he and colleague Sharon A. Rogers, research instructor in medicine, harvested the embryonic pig tissues at precisely the right point in their development.

"When we again harvested the transplant tissues 28 days after fertilization, it reproduced our earlier results, but if we moved the time of harvesting back to 35 days after fertilization, the rats rejected the pig tissues and continued to be diabetic," says Hammerman, who is an endocrinologist and director of the Renal Division at Barnes-Jewish Hospital.

Hammerman and Rogers are leaders in the emerging field of organogenesis, which focuses on growing organs from stem cells and other embryonic cell clusters known as organ primordia. Unlike embryonic stem cells, which can become virtually any cell type, primordia are locked into becoming a particular cell type or one of a particular set of cell types that make up an organ.

In their earlier studies, Hammerman and Rogers had shown that transplantation of pig pancreatic primordia into diabetic rats cures their diabetes permanently without the need for immune suppression. The pig primordia are transplanted into the omentum, a
'"/>

Source:Washington University School of Medicine


Page: 1 2 3

Related biology news :

1. Surgical Robot Scrubs In At UNC, May Be More Precise Than Conventional Surgery
2. Timing is everything: First step in protein building revealed
3. FDA Approves New Drug to Treat Type I and Type II Diabetes
4. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
5. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes

Post Your Comments:
(Date:11/5/2009)...le University have developed synthetic molecules c...HIV and HIV-infected cells, as well as to prostate... the Journal of the American Chemical Society , c...e diseases. , The molecules called "antibody-r...ibody-recruiting molecule targeting prostate cance...
(Date:11/4/2009)...ience) , United States Using Less Water Today ...it did 35 years ago, despite a 30 percent populati...ibutable to alternative cooling methods at power p...ding to the latest USGS water use report, nearly h... cooling thermoelectric power plants. Irrigation a...
(Date:11/4/2009)...t turns out, hold the power to help militaries and...lean up toxic waste on test sites. , Compounds k...d back in World War II and have been used in milit...ounds are often used to propel tank shells and act...th increased knowledge of their environmentally ha...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Genomic research will enable greener cleanup of military explosive test sites 2Watson Prices 24850 Million of Senior Unsecured Notes 54803 1Watson Prices 24850 Million of Senior Unsecured Notes 54803 2Watson Prices 24850 Million of Senior Unsecured Notes 54803 3Lilly Reports on Outcome of Phase III Study of Arzoxifene 54798 1Lilly Reports on Outcome of Phase III Study of Arzoxifene 54798 2Lilly Reports on Outcome of Phase III Study of Arzoxifene 54798 3Lilly Reports on Outcome of Phase III Study of Arzoxifene 54798 4Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 1Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 2Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 3Sen Conrads Health Insurance Co Ops Wont Provide Affordable Care and Could be Used by the Insurance Industry Against Americans Says Consumer Watchdo 54794 4
...y warning system to detect man-made ecological dis...cological Society,s Journal of Applied Ecology has...d on bird song and vocal mimicry, this is the firs... and fragmentation on song-matching. , Ecologists ...upont,s larks, Chersophilus duponti, in Spain and ...
...lable, scientists are increasingly looking for way...determines a protein,s function. In addition to so... information can also help scientists engineer pro... Department of Energy,s Brookhaven National Labora...informational ,wheat, from the ,chaff," said Broo...
...w our arms and legs develop and grow - a finding t...e dismissed as genetic "junk," say scientists at t... The research, available today in the online editi...er bits of RNA called microRNAs act as protective ...tegically turning off gene activity, but by making...
Other Biology News:Pregnancy drugs can affect grandkids 2Scientists develop protein-sequence analysis tool 2MicroRNA may have fail-safe role in limb development 2
(Date:11/5/2009).... 5 Imagenetix, Inc. (OT...iam Spencer, President and CEO of Imagenetix, will...al LD MICRO Conference on Thursday, December 3rd, ... ,, About LD MICRO ,, LD MICRO is a by-invit... undervalued companies in the micro-cap space. Sin...
(Date:11/5/2009)...l on Thursday, November 5, 2009 at 4:30 p.m. Easte...RNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... ) today reported unaudited financial results for ...30, 2009 and reviewed the Company,s highlights for...nsolidated results reflect the operations of OncoG...
(Date:11/5/2009)..., Nov. 5 BioSpecifics Te...ical company developing first-in-class collagenase...ults for the third quarter ended September 30, 200...ber of this year, the FDA,s Arthritis Advisory Com... the approval of XIAFLEX(TM) for the treatment of ...
(Date:11/5/2009)...xas, Nov. 5 Wound Manage...hat it has entered into a Letter of Intent to purc...th Technologies, Inc. (OTC Bulletin Board: VHGI). ...n cash and debt, 4,000,000 shares of WNDM and a ro...the Veriscrip technology being acquired from VHGI....
Breaking Biology Technology:Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
.... 21 /PRNewswire-FirstCall/ - Dr. Brad Thompson, P...ONC, NASDAQ: ONCY), will present a,corporate overv...Forum 2008,on Wednesday, October 29, 2008 at 2:15 ... Hotel in San Francisco from October 29-31, 2008.,... available at:, http://www.corporate-ir.net/ireye/...
...firm that NanoBio,s nanoemulsion technology is eff...ations and vaccines, ANN ARBOR, Mich., Oct. 21 N...esent compelling new data in nine presentations th...inical development programs,in onychomycosis, herp...fluenza vaccine during the joint meeting of the In...
.... 21 Advanced Life Sciences,Holdings, Inc. (Nasda...he,following scientific and investor conference pr...ence call., -- 48th Annual ICAAC/IDSA Annual Meet...ober 28. Advanced Life Sciences will present clini...resentation pertaining to its,lead respiratory ant...
Other Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008 2NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008 2Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 2Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 3
DNA Polymerase I, E. coli from EPICENTRE Biotechnologies
...ce: E. coli strain containing an overproducing cl...e Transcriptase catalyzes the polymerization of DN...ull-length copies of large mRNAs, >10 kb, may be s... lower RNase H activity than AMV Reverse Transcrip...
...Polymerase I catalyzes the template-directed polym...direction. DNA Polymerase I possesses a 3?5 exonuc...owers the error rate during DNA replication, and a...bles the enzyme to replace nucleotides in the grow...
T4 RNA Ligase from Roche Applied Science
Biology Products: